Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$349M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$305M |
| 3 |
iShares Gold Trust
IAU
|
+$282M |
| 4 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$269M |
| 5 |
Blackrock
BLK
|
+$267M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$625M |
| 2 |
NVIDIA
NVDA
|
+$604M |
| 3 |
Tesla
TSLA
|
+$576M |
| 4 |
Microsoft
MSFT
|
+$552M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 40.73% |
| 2 | Technology | 20.55% |
| 3 | Financials | 7.82% |
| 4 | Consumer Discretionary | 7.64% |
| 5 | Communication Services | 5.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5051
CI&T Inc
CINT
$387M
| $7.28K | ﹤0.01% |
+1,219
| New | +$7.02K |
2025 Q2
0 quarters
|
|
5052
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $7.12K | ﹤0.01% |
795
+91
| +13% | +$755 |
2023 Q3
7 quarters
|
|
5053
VistaGen Therapeutics
VTGN
$8.88M
| $7.08K | ﹤0.01% |
3,539
+3,536
| +117,867% | +$8.03K |
2021 Q1
17 quarters
|
|
5054
Contineum Therapeutics
CTNM
$266M
| $7.04K | ﹤0.01% |
1,774
-5,613
| -76% | -$24.4K |
2024 Q2
4 quarters
|
|
5055
CPS Technologies
CPSH
$68.1M
| $6.92K | ﹤0.01% |
+2,500
| New | +$5.33K |
2025 Q2
0 quarters
|
|
5056
Silo Pharma
SILO
$2.42M
| $6.85K | ﹤0.01% |
724
+622
| +610% | +$7.13K |
2024 Q4
2 quarters
|
|
5057
Shattuck Labs
STTK
$544M
| $6.8K | ﹤0.01% |
8,588
-19,955
| -70% | -$19.4K |
2023 Q4
6 quarters
|
|
5058
Avantis International Small Cap Value ETF
AVDV
$20B
| $6.74K | ﹤0.01% |
85
+83
| +4,150% | +$6.14K |
2024 Q4
2 quarters
|
|
5059
Gulf Resources
GURE
$5.66M
| $6.74K | ﹤0.01% |
+1,003
| New | +$6.74K |
2025 Q2
0 quarters
|
|
5060
American Realty Investors
ARL
$267M
| $6.71K | ﹤0.01% |
475
-581
| -55% | -$7.59K |
2022 Q2
12 quarters
|
|
5061
CALL
Core Scientific Inc Tranche 2 Warrants
CORZZ
$1.1B
| $6.64K | ﹤0.01% |
387
| – | – |
2024 Q1
5 quarters
|
|
5062
Comtech Telecommunications
CMTL
$41.6M
| $6.62K | ﹤0.01% |
2,703
+2,701
| +135,050% | +$4.86K |
2013 Q2
48 quarters
|
|
5063
ALPS Sector Dividend Dogs ETF
SDOG
$1.41B
| $6.61K | ﹤0.01% |
+115
| New | +$6.41K |
2025 Q2
0 quarters
|
|
5064
Invesco S&P International Developed Quality ETF
IDHQ
$1.13B
| $6.6K | ﹤0.01% |
200
| – | – |
2018 Q3
27 quarters
|
|
5065
DELISTED
United Homes Group
UHG
| $6.41K | ﹤0.01% |
2,209
-4,276
| -66% | -$11.1K |
2023 Q2
8 quarters
|
|
5066
Bicycle Therapeutics
BCYC
$242M
| $6.34K | ﹤0.01% |
913
+224
| +33% | +$1.78K |
2021 Q1
17 quarters
|
|
5067
VanEck Natural Resources ETF
HAP
$338M
| $6.29K | ﹤0.01% |
121
-39
| -24% | -$1.93K |
2021 Q4
14 quarters
|
|
5068
Diana Shipping
DSX
$311M
| $6.26K | ﹤0.01% |
+4,286
| New | +$6.44K |
2025 Q2
0 quarters
|
|
5069
Amarin Corp
AMRN
$239M
| $6.21K | ﹤0.01% |
383
+92
| +32% | +$1.03K |
2013 Q2
48 quarters
|
|
5070
Northern Technologies International Corp
NTIC
$73.2M
| $6.16K | ﹤0.01% |
831
-4,884
| -85% | -$37.3K |
2024 Q2
4 quarters
|
|
5071
Harvard Bioscience
HBIO
$36.8M
| $6.14K | ﹤0.01% |
1,383
-1,557
| -53% | -$6.51K |
2023 Q2
8 quarters
|
|
5072
CervoMed
CRVO
$33.9M
| $6.04K | ﹤0.01% |
961
-2,884
| -75% | -$24.6K |
2024 Q2
4 quarters
|
|
5073
First Trust Small Cap Value AlphaDEX Fund
FYT
$171M
| $5.87K | ﹤0.01% |
116
| – | – |
2024 Q2
4 quarters
|
|
5074
DELISTED
Monogram Orthopaedics
MGRM
| $5.78K | ﹤0.01% |
2,000
| – | – |
2024 Q4
2 quarters
|
|
5075
Incannex Healthcare Limited Common Stock
IXHL
$35.4M
| $5.71K | ﹤0.01% |
+882
| New | +$8.72K |
2025 Q2
0 quarters
|
|
Similar funds
Citigroup's Q2 2025 Portfolio in Review
As of Q2 2025, Citigroup held 6,003 positions worth $204B, up 4.1% from $196B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Citigroup's Q2 2025 filing shows 467 new, 1,653 increased, 2,974 reduced and 377 closed positions. Its largest new stake was Amrize Ltd: 2,294,135 shares worth $114M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $625M.
By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
- Citigroup's largest Q2 2025 buy was Amrize Ltd: 2,294,135 shares worth $114M.
- Citigroup added most to Bank of America in Q2 2025, an estimated $349M increase.
- Citigroup's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $625M.
- Citigroup fully exited James Hardie Industries in Q2 2025, selling an estimated $125M.
- Citigroup's ten largest holdings make up 20% of its $204B portfolio in Q2 2025.
- Citigroup opened 467 new positions and closed 377 in Q2 2025.
- Citigroup's portfolio value rose 4.1% quarter-over-quarter to $204B.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.